CareDx Company Profile (NASDAQ:CDNA)

About CareDx (NASDAQ:CDNA)

CareDx logoCareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Diagnostics & Testing
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CDNA
  • CUSIP: N/A
  • Web:
  • Market Cap: $44.63 million
  • Outstanding Shares: 22,541,000
Average Prices:
  • 50 Day Moving Avg: $1.38
  • 200 Day Moving Avg: $1.45
  • 52 Week Range: $0.76 - $4.98
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.88
  • P/E Growth: -0.11
Sales & Book Value:
  • Annual Revenue: $46.96 million
  • Price / Sales: 0.95
  • Book Value: $0.55 per share
  • Price / Book: 3.60
  • EBIDTA: ($9,830,000.00)
  • Net Margins: -61.27%
  • Return on Equity: -85.68%
  • Return on Assets: -21.21%
  • Current Ratio: 0.37%
  • Quick Ratio: 0.32%
  • Average Volume: 322,814 shs.
  • Beta: 0.78
  • Short Ratio: 0.72

Frequently Asked Questions for CareDx (NASDAQ:CDNA)

What is CareDx's stock symbol?

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

How were CareDx's earnings last quarter?

CareDx, Inc. (NASDAQ:CDNA) issued its earnings results on Thursday, August, 10th. The company reported ($0.19) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.19). The firm had revenue of $12.05 million for the quarter, compared to analyst estimates of $11.87 million. CareDx had a negative net margin of 61.27% and a negative return on equity of 85.68%. View CareDx's Earnings History.

What guidance has CareDx issued on next quarter's earnings?

CareDx issued an update on its first quarter earnings guidance on Monday, May, 22nd. The company provided EPS guidance of ($0.32-0.27) for the period, compared to the Thomson Reuters consensus estimate of ($0.19). The company issued revenue guidance of $11.4-11.6 million, compared to the consensus revenue estimate of $11.22 million.

Who are some of CareDx's key competitors?

Who are CareDx's key executives?

CareDx's management team includes the folowing people:

  • Michael D. Goldberg, Independent Chairman of the Board
  • Peter Maag Ph.D., President, Chief Executive Officer, Director
  • Michael Bell, Chief Financial Officer
  • Mitchell J. Nelles Ph.D., Chief Operating Officer
  • John J. Sninsky Ph.D., Chief Scientific Officer
  • Josh DeFonzo, Chief Commercial Officer
  • Matthew J. Meyer, Chief Business Officer
  • James P. Yee M.D., Ph.D., Chief Medical Officer
  • George W. Bickerstaff III, Independent Director
  • Fred E. Cohen Ph.D. M.D., Independent Director

Who owns CareDx stock?

CareDx's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Gagnon Securities LLC (9.73%), Paragon Associates & Paragon Associates II Joint Venture (5.95%), Gagnon Advisors LLC (4.45%), Royce & Associates LP (3.42%), Vanguard Group Inc. (1.16%) and Stonepine Capital Management LLC (0.89%). Company insiders that own CareDx stock include Michael Brian Bell, Neil Gagnon and Peter Maag. View Institutional Ownership Trends for CareDx.

Who sold CareDx stock? Who is selling CareDx stock?

CareDx's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for CareDx.

Who bought CareDx stock? Who is buying CareDx stock?

CareDx's stock was acquired by a variety of institutional investors in the last quarter, including Royce & Associates LP, Stonepine Capital Management LLC, Gagnon Securities LLC and Gagnon Advisors LLC. Company insiders that have bought CareDx stock in the last two years include Michael Brian Bell, Neil Gagnon and Peter Maag. View Insider Buying and Selling for CareDx.

How do I buy CareDx stock?

Shares of CareDx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CareDx's stock price today?

One share of CareDx stock can currently be purchased for approximately $1.98.

MarketBeat Community Rating for CareDx (NASDAQ CDNA)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  79 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  144
MarketBeat's community ratings are surveys of what our community members think about CareDx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CareDx (NASDAQ:CDNA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for CareDx (NASDAQ:CDNA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/15/2016Piper Jaffray CompaniesReiterated RatingOverweight$6.00N/AView Rating Details
6/14/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
6/14/2016MizuhoBoost Price TargetBuy$8.00 -> $12.00N/AView Rating Details
2/9/2016Janney Montgomery ScottInitiated CoverageBuy -> Buy$12.00N/AView Rating Details
11/18/2015Craig HallumBoost Price TargetBuy$10.00 -> $13.00N/AView Rating Details
9/28/2015Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 8/20/2015 forward)


Earnings History for CareDx (NASDAQ:CDNA)
Earnings by Quarter for CareDx (NASDAQ:CDNA)
Earnings History by Quarter for CareDx (NASDAQ CDNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/10/2017Q2 2017($0.19)($0.19)$11.87 million$12.05 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.25)($0.17)$11.50 million$12.48 millionViewListenView Earnings Details
8/10/2016Q216($0.28)($0.29)$10.42 million$10.70 millionViewListenView Earnings Details
5/6/2016Q1($0.31)($0.37)$6.97 million$6.60 millionViewN/AView Earnings Details
3/24/2016Q415($0.34)($0.40)$7.44 million$6.60 millionViewListenView Earnings Details
11/11/2015Q315($0.25)($0.29)$7.34 million$7.15 millionViewListenView Earnings Details
8/10/2015Q215($0.18)($0.27)$7.28 million$7.13 millionViewListenView Earnings Details
5/12/2015Q115($0.17)($0.19)$6.82 million$7.22 millionViewListenView Earnings Details
11/10/2014Q314($0.13)$0.01$6.60 million$6.65 millionViewN/AView Earnings Details
8/27/2014Q2 14($0.13)($0.09)$6.18 million$6.78 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for CareDx (NASDAQ:CDNA)
Current Year EPS Consensus Estimate: $-0.82 EPS
Next Year EPS Consensus Estimate: $-0.51 EPS


Dividend History for CareDx (NASDAQ:CDNA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for CareDx (NASDAQ:CDNA)
Insider Ownership Percentage: 5.40%
Institutional Ownership Percentage: 35.58%
Insider Trades by Quarter for CareDx (NASDAQ:CDNA)
Institutional Ownership by Quarter for CareDx (NASDAQ:CDNA)
Insider Trades by Quarter for CareDx (NASDAQ:CDNA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2017Michael Brian BellCFOBuy725$1.83$1,326.75View SEC Filing  
8/15/2017Peter MaagInsiderBuy600$1.82$1,092.00View SEC Filing  
7/24/2017Neil GagnonMajor ShareholderBuy1,486$1.23$1,827.78View SEC Filing  
6/29/2017Neil GagnonMajor ShareholderBuy1,808$1.11$2,006.88View SEC Filing  
6/23/2017Neil GagnonMajor ShareholderBuy63,120$1.10$69,432.00View SEC Filing  
5/24/2017Neil GagnonMajor ShareholderBuy7,439$1.00$7,439.00View SEC Filing  
5/23/2017Neil GagnonMajor ShareholderBuy6,836$1.04$7,109.44View SEC Filing  
4/28/2017Neil GagnonMajor ShareholderBuy15,116$0.89$13,453.24View SEC Filing  
3/16/2017Neil GagnonMajor ShareholderBuy123,160$1.83$225,382.80View SEC Filing  
9/22/2016Neil GagnonMajor ShareholderBuy178,686$4.00$714,744.00View SEC Filing  
4/14/2016Neil GagnonMajor ShareholderBuy93,240$4.02$374,824.80View SEC Filing  
10/21/2015Neil Gagnonmajor shareholderBuy1,431$4.99$7,140.69View SEC Filing  
10/20/2015Neil GagnonMajor ShareholderBuy1,347$4.92$6,627.24View SEC Filing  
9/29/2015Neil Gagnonmajor shareholderBuy6,332$6.10$38,625.20View SEC Filing  
9/4/2015Neil GagnonMajor ShareholderBuy69,383$6.95$482,211.85View SEC Filing  
6/5/2015Neil GagnonMajor ShareholderBuy6,500$5.69$36,985.00View SEC Filing  
6/1/2015Peter MaagCEOBuy2,000$4.84$9,680.00View SEC Filing  
4/17/2015Neil GagnonMajor ShareholderBuy13,051$5.34$69,692.34View SEC Filing  
3/20/2015Neil GagnonMajor ShareholderBuy6,324$6.35$40,157.40View SEC Filing  
2/27/2015Neil GagnonMajor ShareholderBuy4,270$6.03$25,748.10View SEC Filing  
2/6/2015Neil GagnonMajor ShareholderBuy4,586$7.20$33,019.20View SEC Filing  
2/5/2015Neil GagnonMajor ShareholderBuy121,587$7.10$863,267.70View SEC Filing  
2/4/2015Neil GagnonMajor ShareholderBuy31,991$7.00$223,937.00View SEC Filing  
2/3/2015Neil GagnonMajor ShareholderBuy23,558$7.03$165,612.74View SEC Filing  
2/2/2015Neil GagnonMajor ShareholderBuy3,620$7.05$25,521.00View SEC Filing  
1/29/2015Neil GagnonMajor ShareholderBuy15,395$7.04$108,380.80View SEC Filing  
1/27/2015Neil GagnonMajor ShareholderBuy84,720$7.00$593,040.00View SEC Filing  
1/22/2015Neil GagnonMajor ShareholderBuy48,670$7.13$347,017.10View SEC Filing  
1/20/2015Neil GagnonMajor ShareholderBuy16,192$6.66$107,838.72View SEC Filing  
1/15/2015Neil GagnonMajor ShareholderBuy39,109$6.43$251,470.87View SEC Filing  
1/14/2015Neil GagnonMajor ShareholderBuy122,319$7.07$864,795.33View SEC Filing  
7/22/2014Ken LudlumCFOBuy7,000$10.00$70,000.00View SEC Filing  
7/22/2014Michael GoldbergDirectorBuy25,000$10.00$250,000.00View SEC Filing  
7/22/2014Perkins Caufield & Bye KleinerMajor ShareholderBuy52,770$10.00$527,700.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for CareDx (NASDAQ:CDNA)
Latest Headlines for CareDx (NASDAQ:CDNA)
DateHeadline logoEdited Transcript of CDNA earnings conference call or presentation 10-Aug-17 8:30pm GMT - August 11 at 5:31 PM logo Analysts Expect CareDx, Inc. (CDNA) Will Announce Quarterly Sales of $12.01 Million - August 11 at 4:04 PM logoCareDx, Inc. (NASDAQ:CDNA) Releases Earnings Results, Meets Expectations - August 11 at 2:34 PM logoInvestor Network: CareDx, Inc. to Host Earnings Call - August 10 at 11:13 PM logoCareDx Reports Second Quarter 2017 Financial Results - August 10 at 11:13 PM logoComparing Digiliti Money (DGLT) & CareDx (NASDAQ:CDNA) - August 10 at 8:22 PM logoCritical Analysis: Lion Biotechnologies (IOVA) versus CareDx (NASDAQ:CDNA) - August 10 at 3:20 PM logo-$0.20 EPS Expected for CareDx, Inc. (CDNA) This Quarter - August 9 at 7:46 AM logoCareDx Describes Extensive Analytical Validation Data on AlloSure Robustness at American Association of Clinical Chemistry Annual Meeting - August 4 at 5:17 PM logoCareDx, Inc. (NASDAQ:CDNA) Scheduled to Post Earnings on Tuesday - August 1 at 7:16 AM logoAnalyzing Vermillion (VRML) & CareDx (CDNA) - July 28 at 7:53 AM logoCareDx to Announce Second Quarter 2017 Financial Results on August 10, 2017 - July 27 at 4:28 PM logo$11.87 Million in Sales Expected for CareDx, Inc. (NASDAQ:CDNA) This Quarter - July 22 at 12:44 PM logoReviewing CareDx (CDNA) and Digiliti Money (DGLT) - July 21 at 12:06 AM logo-$0.20 Earnings Per Share Expected for CareDx, Inc. (NASDAQ:CDNA) This Quarter - July 20 at 9:15 AM logo100,000th AlloMap Result Provided to Heart Transplant Patients - July 13 at 6:03 PM logoAsset Acquisitions Accelerate in Healthcare Sector Boosting Potential Revenue Growth - July 11 at 6:05 PM logoETFs with exposure to CareDx, Inc. : July 10, 2017 - July 10 at 5:01 PM logoCareDx, Inc. (NASDAQ:CDNA) Stock Rating Upgraded by Zacks Investment Research - July 4 at 6:32 PM logoCareDx Restructures and Defers Certain Obligations to March 2019 - July 3 at 5:03 PM logoETFs with exposure to CareDx, Inc. : June 28, 2017 - June 28 at 5:02 PM logoInsider Buying: CareDx, Inc. (CDNA) Major Shareholder Purchases 63,120 Shares of Stock - June 27 at 1:20 PM logo$11.86 Million in Sales Expected for CareDx, Inc. (CDNA) This Quarter - June 25 at 7:40 AM logoZacks: Analysts Anticipate CareDx, Inc. (CDNA) to Announce -$0.16 EPS - June 23 at 10:20 PM logoETFs with exposure to CareDx, Inc. : June 16, 2017 - June 16 at 4:58 PM logoMyriad Genetics (MYGN) versus CareDx (CDNA) Head to Head Contrast - June 14 at 8:20 PM logoCareDx, Inc. :CDNA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 - June 14 at 4:58 PM logoCareDx, Inc. (CDNA) Rating Lowered to Strong Sell at ValuEngine - June 11 at 8:58 PM logoCareDx Inc (CDNA) Upgraded by Zacks Investment Research to "Buy" - June 9 at 8:21 PM logoCareDx Reports First Quarter 2017 Financial Results - June 9 at 4:49 PM logoCareDx reports 1Q loss - June 9 at 4:49 PM logoZacks Investment Research Downgrades CareDx Inc (CDNA) to Hold - June 8 at 5:56 PM logoCareDx (CDNA) & National Research (NRCIB) Head to Head Analysis - June 5 at 4:10 PM logo$11.23 Million in Sales Expected for CareDx Inc (CDNA) This Quarter - June 1 at 10:08 AM logoCareDx Activities at European Federation of Immunogenetics Congress - May 30 at 12:09 PM logoCareDx Inc (CDNA) Upgraded at Zacks Investment Research - May 25 at 7:58 PM logoCareDx (CDNA) Receives Letter from Nasdaq Regarding Non-Compliance with Listing Rule - May 24 at 9:07 PM logoEdited Transcript of CDNA earnings conference call or presentation 22-May-17 8:30pm GMT - May 23 at 4:13 PM logoCareDx Inc (CDNA) Updates Q1 Earnings Guidance - May 22 at 5:10 PM logoCareDx Reports Preliminary First Quarter 2017 Financial Results - May 22 at 4:07 PM logoCareDx to Announce First Quarter 2017 Preliminary Financial Results on May 22, 2017 - May 19 at 8:52 AM logoZacks Investment Research Upgrades CareDx Inc (CDNA) to "Hold" - May 16 at 6:26 PM logoShort Interest in CareDx Inc (CDNA) Drops By 72.0% - May 14 at 9:14 AM logoZacks: Analysts Expect CareDx Inc (CDNA) Will Post Quarterly Sales of $11.01 Million - May 6 at 7:38 AM logo-$0.22 EPS Expected for CareDx Inc (CDNA) This Quarter - May 4 at 11:40 PM logoCareDx Achieves Significant Milestone Towards CMS Coverage for AlloSure - May 4 at 4:20 PM logoCareDx Inc (CDNA) Major Shareholder Neil Gagnon Buys 15,116 Shares - May 4 at 12:36 AM logoCareDx (CDNA) Receives Daily News Sentiment Score of 0.12 - May 3 at 11:52 PM logoInsider Buying: CareDx Inc (CDNA) Major Shareholder Buys 15,116 Shares of Stock - May 2 at 10:54 PM logoETFs with exposure to CareDx, Inc. : April 28, 2017 - April 28 at 5:10 PM



CareDx (CDNA) Chart for Sunday, August, 20, 2017

This page was last updated on 8/20/2017 by Staff